-
HSV-2 shell particles: Progress in the study of the assembly mechanism of herpes virus nuclear case.
Time of Update: 2020-08-10
Junzhi of the China Institute of Food and Drug Inspection, etc., for the first time, analyzed the herpes virus alpha family type 2 herpes simplex virus (HSV-- 2) The 3.1A atomic resolution structure of the nuclear coat shell clarifies the complex
-
For liver cancer! Keystone Pharmaceuticals PD-1 antibodies are qualified by the U.S. FDA for orphan drugs.
Time of Update: 2020-08-09
Today, Keystone Pharmaceuticals announced that the U.S. FDA has granted its PD-1 antibody CS1003 orphan drug eligibility for the treatment of liver cell carcinoma. CS1003 is one of the products of tumor immunoskeleton in Keystone
-
Jiahe Bio-Bio PD-1 Monoto-list application is to be included in the priority review.
Time of Update: 2020-08-08
According to the website of the Pharmaceutical Review Center of the National Drug Administration of China (NMPA), Jiahe Bio's PD-1 monoantinomonotagated (geptanolimab, research and development code GB226) was included in the priority list for review
-
The high-resolution 3D structure of the mature nuclear shell of herpes simplex virus type 2 was analyzed.
Time of Update: 2020-08-08
of Hunan Normal University. the work reported on the atomic resolution structure of cvSC 3.75 angstrom of CVSC around the herpes virus alpha family (HSV-2) C, which the team has developed after analyzing the 3D fine structure of HSV-2 B particles
-
PD-L1-CTLA-4 bispecific antibodies developed by Corning Jerry are about to enter clinical trials.
Time of Update: 2020-08-07
On October 11, Jiangsu Corning Jerry Biopharmaceutical Co., Ltd. ("Jiangsu Corning Jerry") announced that its independent research and development of the world's first recombinant humanized PD-L1-CTLA-4 bispecific antibodies (product code: KN046
-
Lancet's paper is detailed! Phase 2 clinical trialshows that the new new crown candidate vaccine developed in China has great potential.
Time of Update: 2020-08-06
, which provides clinical information for the phase 3 clinical application of this candidate vaccine. , however, the Chinese researchers who led the study noted that it was important to note that no participants had been exposed to the new
-
2 cases of melanin neuropathy were reported.
Time of Update: 2020-08-06
, stove, PR), SOX-10 (cook, S-100), HMB45 (plus), MelanA (plus), Ki-67 (5%), NeuN (cooker), diagnosis of melanoma CLASS I (Figure 2). Case 2: The patient, male, 55, was admitted to hospital in March due to head and neck pain. admission
-
E2-2, a member of the E protein family, is able to influence the function of the AETFC composite.
Time of Update: 2020-08-06
of the Shanghai Institute of Nutrition and Health of the Chinese Academy of Sciences and Sun Xiaojian Research Group of Ruijin Hospital, affiliated with Shanghai Jiaotong University, and Robert G. Roeder of Rockefeller University in the United States. E2-2
-
Enter the field of breast cancer! Mercadon Keytruda (Corrida) 2 applications were accepted
Time of Update: 2020-08-06
new supplementary biological licenses (TNBC). FDA has granted one of the sBLA priority reviews, which seeks to expedite approval of Keytruda combined chemotherapy for the treatment of local recurrent non-recitability or metastatic TNBC patients
-
Nature papers read in detail! In some healthy people, SARS-CoV-2 reactive T cells exist.
Time of Update: 2020-08-06
!--:page title"----- In a new study, researchers from the SchallitSchool School of Medicine in Berlin, Germany, and the Max Planck Institute for Molecular Genetics found that some healthy people have immune cells that recognize the new coronavirus SARS-CoV-2.
-
Diabetes Care: Incidence of red blood cell n-6 polyunsaturated fatty acids, intestinal flora, and type 2 diabetes.
Time of Update: 2020-08-06
A recent study published in Diabetes Care, an authoritative journal of diabetes, looked at the association between red blood cell n-6 polyunsaturated fatty acids (PUFA) biomarkers and type 2 diabetes and the potential role of intestinal flora
-
For the new coronavirus SARS-CoV-2/COVID-19, the Latest Research Progress in nature Journal (No. 3)
Time of Update: 2020-08-06
. coronavirus can cause multi-system infections in a variety of animals. had previously had six coronaviruses that could infect humans, mainly causing respiratory infections in humans: two highly deadly coronaviruses, severe acute
-
Science: Detailed explanation of our scientists have developed a SARS-CoV-2 strain adapted to mice that can be used to test vaccine efficacy.
Time of Update: 2020-08-06
-active wild types. In addition, they tested the protective effect of a newly developed recombinant subunit candidate vaccine in a mouse model that challenged the SARS-CoV-2 strain. related findings were published online July 30, 2020
-
Scientists may be able to use gut microbes to develop preventive and therapeutic measures for type 2 diabetes.
Time of Update: 2020-08-06
29, 2020 /PRNewswire/ -- In a recent study published in the international journal Cell Metabolism entitled "The Gut Microbiota in Prediabetes and Diabetes: A Population-Based Cross-Sectional Study", scientists from institutions
-
Medical researchers at the University of Cambridge have found that branched chain amino acids are associated with an increased risk of type 2 diabetes.
Time of Update: 2020-08-06
researchers studied more than 10 million genetic variants in more than 16,000 men and women and found genetic differences in five human genome regions associated with higher levels of circulating branched chain amino acids.
-
JCC: The use of metformin reduces the risk of inflammatory bowel disease in patients with type 2 diabetes.
Time of Update: 2020-08-06
with type 2 diabetes between 1999 and 2005, and as of January 1, 2006, 340,211 users who had used IBD and 24,478 users who had never used IT were followed up. the risk ratio was estimated by Cox regression and the treatment weighting was used
-
PD-L1 Single Anti-Bavencio plus Asitini: Recommended by NICE in the UK as a first-line treatment for advanced kidney cancer.
Time of Update: 2020-08-06
The National Institute for Health and Care Excellence (NICE) recommends that Merck and Pfizer's immunotherapy bavenio (avelumib) be combined with Inlyta (axinitib) for first-line treatment syntil-end renal cell carcinoma (RCC).
-
Domestic PD-1 growth rate is amazing, the first half of sales close to the o drug year- through.
Time of Update: 2020-08-06
the product sales have been close to the full year of 2019 1 billion yuan, but also close to O Drug 2019 China sales, domestic PD-1 growth rate is really amazing. it is understood that Daberschu is an innovative PD-1 inhibitor developed by Cinda Bio
-
Anti-CD47 / PD-L1 Bispecific Antibody Clinical Trials: The first patient in China has entered the group.
Time of Update: 2020-08-06
Biopharmaceuticalcompany Innoventannounc today announced that the Phase I clinical trial (CIBI32A101) of recombinant anti-CD47/PD-L1 bispecific antibodies (IBI322) has officially begun and the first patients in China have entered the group.
-
Roche PD-L1 monoanti-Tecentriq joint targeted therapy: FDA approved for treatment of advanced melanoma.
Time of Update: 2020-08-06
Roche announced that the U.S. Food and Drug Administration (FDA) has approved its PD-L1 monoantitic Tecentriq joint MEK inhibitor Cotellic (cobimetinib) and BRAF inhibitor Zelmurabraf for the treatment of patients with braF V600 mutation-positive advanced melanoma.
